GlassScriptPhysician profile
Keith Pennycook
NPI 1821651944
$15,027.30
in general payments reported to CMS, 2019-2025
26 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $649 · 2021: $2,080 · 2022: $5,592 · 2023: $3,655 · 2024: $1,839 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,832 · Consulting Fee: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,832.03 |
| Consulting Fee | $875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $3,388.29 | 2022-2024 | Vtama |
| Abbvie INC. | $2,174.06 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $2,034.42 | 2023-2025 | Zoryve |
| Genzyme Corporation | $976.40 | 2021-2025 | |
| Galderma Laboratories, L.P. | $891.42 | 2020-2025 | Nemluvio, Oracea, Twyneo |
| Pfizer INC. | $582.09 | 2020-2024 | |
| Amgen INC. | $508.02 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $484.11 | 2024-2025 | Adbry |
| Ucb, INC. | $475.27 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $449.39 | 2021-2025 | Jublia, Targretin, Siliq |
| Epi Health, LLC | $429.43 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $375.84 | 2021-2025 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $333.93 | 2022-2024 | Sotyktu |
| Journey Medical Corporation | $331.49 | 2022-2024 | |
| Incyte Corporation | $328.37 | 2022-2024 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $319.02 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $256.87 | 2021-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $140.26 | 2020-2025 | |
| Organon LLC | $133.34 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $123.13 | 2025 | Tremfya |
| Almirall LLC | $117.36 | 2020-2022 | |
| Lilly USA, LLC | $62.09 | 2022 | |
| Novartis Pharmaceuticals Corporation | $58.50 | 2024 | |
| Botanix Sb INC | $21.32 | 2025 | Sofdra |
| Janssen Biotech, INC. | $17.19 | 2025 | Tremfya |
| Lnhc, INC | $15.69 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Pennycook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.